Latest Diamedica Inc (DMCAF) Headlines
Aon Benfield Exec: China Moving Towards Second Generation of Solvency Regime
Iris Lai - AMBest - Tue Feb 25, 11:08AM CST
China sees the need to move toward a new generation of solvency regime in light of global regulatory trends, the country's current market conditions and insurance growth over the past decade, according to Sifang Zhang, head of rating agency advisory at intermediary Aon Benfield.
Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International Capnography Market 2012 - Forecasts to 2016
M2 - Mon Jan 13, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/g7h4gv/global) has announced the addition of the "2013 Report on the International Capnography Market 2012 - Forecasts to 2016" report to their offering. Advancements in capnography technology are allowing critical care providers to have a more accurate way of measuring CO2 in critical care patients. Although healthcare professionals have experienced major difficulties and limitations when using Mainstream and Sidestream capnography over the past few years, the latest Microstream capnography technology is expected to overcome those drawbacks. Microstream technology helps care providers monitor both intubated and non-intubated patients. Devices based on this technology can operate in extremely humid environments, in homecare, ambulatory services, and in hospitals. Microstream devices also offer improved moisture management to eliminate problems caused by blocked sample lines. One of the major growth drivers is the tremendous advancements in technology being made in the form of innovations that have led to the development of new-generation capnography devices. For example, Oridion's Microstream technology created a revolution in the Global Capnography market. Moreover, potential users in the APAC region are also expected to boost the market during the forecast period. These factors in combination with others are expected to drive the growth of the Global Capnography market during the forecast period. The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are CAS Medical Systems Inc., Diamedica Inc., Dragerwerk AG & Co. KGaA, GE Healthcare Ltd., Ivy Biomedical Systems Inc., Medtronic Inc., Nihon Kohden Corp. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - CAS Medical Systems - Covidien - Diamedica - Dragerwerk AG & Co. KGaA - GE Healthcare - Ivy Biomedical Systems - Medtronic - Nihon Kohden - Nonin Medical - OSI Systems - Opto Circuits (India) - Philips Healthcare - Smiths Medical - Triton Electronics - Weinmann Gerate fur Medizin - Welch Allyn Inc. For more information visit http://www.researchandmarkets.com/research/g7h4gv/global
DiaMedica Inc. Announces Results of Annual General and Special Meeting
Marketwire - Fri Dec 20, 4:52PM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General and Special Meeting (the "Meeting") of shareholders of DiaMedica held on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were re-elected as the board of directors of DiaMedica.
DiaMedica Inc. Announces Public Offering
Marketwire - Wed Dec 04, 11:13AM CST
DiaMedica Inc. (TSX VENTURE: DMA), announced today that it has filed a preliminary short form prospectus in connection with the public offering (the "Offering") of units of DiaMedica (the "Units"). The Offering is being placed on a commercially reasonable efforts agency basis by Jordan Capital Markets Inc. (the "Agent").
DiaMedica Issues Stock Option Grant
Marketwire - Mon Nov 11, 4:01PM CST
DiaMedica Inc. (TSX VENTURE: DMA), announces that the Board of Directors has granted options to purchase 100,000 common shares of the Corporation to its directors as part of its bi-annual stock option issuance. The options were issued at an exercise price of $0.86 per share for a ten-year term.
Diabetic Neuropathy - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bgwcx/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2013" report to their offering. 'Diabetic Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. Scope - A snapshot of the global therapeutic scenario for Diabetic Neuropathy. - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Takeda Pharmaceutical Company Limited Dong-A Pharmaceutical Co., Ltd. Neuralstem, Inc. Lpath, Inc. DiaMedica Inc. R-Tech Ueno, Ltd. Neurotune AG Intellect Neurosciences, Inc. Glucox Biotech Vascular Pharmaceuticals, Inc. TheraQuest Biosciences, LLC For more information visit http://www.researchandmarkets.com/research/9bgwcx/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Influenza - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Influenza
M2 - Wed Sep 04, 11:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zj34n7/influenza) has announced the addition of the "Influenza - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Influenza. - A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 4SC AG - AIMM Therapeutics B.V. - Amarillo Biosciences, Inc. - BioAlliance Pharma SA - Biotron Limited - CEL-SCI Corporation - DiaMedica Inc. - Evolva SA - Functional Genetics, Inc. - Generex Biotechnology Corporation - GlaxoSmithKline plc - Green Cross Corporation - Hawaii Biotech, Inc. - Inovio Biomedical Corporation - Johnson & Johnson - Novartis AG - Novavax, Inc. - Okairos - Panacea Biotec Limited - PaxVax - PepTcell Limited - Quantum Pharmaceuticals - Romark Laboratories, L.C. - Sanofi-Aventis - Trellis Bioscience, Inc. - UMN Pharma Inc. - Vivaldi Biosciences Inc. - Wittycell S.A.S. - XOMA Ltd. - Zosano Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/zj34n7/influenza About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer
M2 - Wed Jun 05, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g6cvrj/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Pancreatic Cancer products under dev
DiaMedica Announces Initiation of Phase I/II Clinical Trial for Potential First-in-Class Treatment of Type 2 Diabetes
Marketwire Canada - Wed May 01, 7:07AM CDT
DiaMedica Inc. (TSX VENTURE
MA) announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a recombinant protein therapy for the treatment of diabetes and associated complications. As described in the April 8th 2013 press release, the study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients.
DiaMedica to Present at 15th Annual BIO CEO & Investor Conference
Marketwire - Tue Feb 05, 7:30AM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on developing novel treatments for diabetes, announced that Mr. Rick Pauls, Chairman & Chief Executive Officer, will provide a corporate overview at the 15th annual BIO CEO & Investor conference on Monday February 11, 2013 at 10 am ET at the Waldorf Astoria Hotel in New York City.
Aon Benfield Exec: China Moving Towards Second Generation of Solvency Regime
Iris Lai - AMBest - Tue Feb 25, 11:08AM CST
China sees the need to move toward a new generation of solvency regime in light of global regulatory trends, the country's current market conditions and insurance growth over the past decade, according to Sifang Zhang, head of rating agency advisory at intermediary Aon Benfield.
Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
2013 Report on the International Capnography Market 2012 - Forecasts to 2016
M2 - Mon Jan 13, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/g7h4gv/global) has announced the addition of the "2013 Report on the International Capnography Market 2012 - Forecasts to 2016" report to their offering. Advancements in capnography technology are allowing critical care providers to have a more accurate way of measuring CO2 in critical care patients. Although healthcare professionals have experienced major difficulties and limitations when using Mainstream and Sidestream capnography over the past few years, the latest Microstream capnography technology is expected to overcome those drawbacks. Microstream technology helps care providers monitor both intubated and non-intubated patients. Devices based on this technology can operate in extremely humid environments, in homecare, ambulatory services, and in hospitals. Microstream devices also offer improved moisture management to eliminate problems caused by blocked sample lines. One of the major growth drivers is the tremendous advancements in technology being made in the form of innovations that have led to the development of new-generation capnography devices. For example, Oridion's Microstream technology created a revolution in the Global Capnography market. Moreover, potential users in the APAC region are also expected to boost the market during the forecast period. These factors in combination with others are expected to drive the growth of the Global Capnography market during the forecast period. The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are CAS Medical Systems Inc., Diamedica Inc., Dragerwerk AG & Co. KGaA, GE Healthcare Ltd., Ivy Biomedical Systems Inc., Medtronic Inc., Nihon Kohden Corp. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - CAS Medical Systems - Covidien - Diamedica - Dragerwerk AG & Co. KGaA - GE Healthcare - Ivy Biomedical Systems - Medtronic - Nihon Kohden - Nonin Medical - OSI Systems - Opto Circuits (India) - Philips Healthcare - Smiths Medical - Triton Electronics - Weinmann Gerate fur Medizin - Welch Allyn Inc. For more information visit http://www.researchandmarkets.com/research/g7h4gv/global
DiaMedica Inc. Announces Results of Annual General and Special Meeting
Marketwire - Fri Dec 20, 4:52PM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on diabetes, is pleased to announce that at the Annual General and Special Meeting (the "Meeting") of shareholders of DiaMedica held on December 16, 2013, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas Wellner were re-elected as the board of directors of DiaMedica.
DiaMedica Inc. Announces Public Offering
Marketwire - Wed Dec 04, 11:13AM CST
DiaMedica Inc. (TSX VENTURE: DMA), announced today that it has filed a preliminary short form prospectus in connection with the public offering (the "Offering") of units of DiaMedica (the "Units"). The Offering is being placed on a commercially reasonable efforts agency basis by Jordan Capital Markets Inc. (the "Agent").
DiaMedica Issues Stock Option Grant
Marketwire - Mon Nov 11, 4:01PM CST
DiaMedica Inc. (TSX VENTURE: DMA), announces that the Board of Directors has granted options to purchase 100,000 common shares of the Corporation to its directors as part of its bi-annual stock option issuance. The options were issued at an exercise price of $0.86 per share for a ten-year term.
Diabetic Neuropathy - Pipeline Review, H2 2013
M2 - Wed Oct 09, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9bgwcx/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H2 2013" report to their offering. 'Diabetic Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy. Scope - A snapshot of the global therapeutic scenario for Diabetic Neuropathy. - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Diabetic Neuropathy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Merck & Co., Inc. Dainippon Sumitomo Pharma Co., Ltd. Takeda Pharmaceutical Company Limited Dong-A Pharmaceutical Co., Ltd. Neuralstem, Inc. Lpath, Inc. DiaMedica Inc. R-Tech Ueno, Ltd. Neurotune AG Intellect Neurosciences, Inc. Glucox Biotech Vascular Pharmaceuticals, Inc. TheraQuest Biosciences, LLC For more information visit http://www.researchandmarkets.com/research/9bgwcx/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Influenza - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Influenza
M2 - Wed Sep 04, 11:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zj34n7/influenza) has announced the addition of the "Influenza - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Influenza - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late-stage and discontinued projects. Influenza - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Influenza. - A review of the Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Influenza pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - 4SC AG - AIMM Therapeutics B.V. - Amarillo Biosciences, Inc. - BioAlliance Pharma SA - Biotron Limited - CEL-SCI Corporation - DiaMedica Inc. - Evolva SA - Functional Genetics, Inc. - Generex Biotechnology Corporation - GlaxoSmithKline plc - Green Cross Corporation - Hawaii Biotech, Inc. - Inovio Biomedical Corporation - Johnson & Johnson - Novartis AG - Novavax, Inc. - Okairos - Panacea Biotec Limited - PaxVax - PepTcell Limited - Quantum Pharmaceuticals - Romark Laboratories, L.C. - Sanofi-Aventis - Trellis Bioscience, Inc. - UMN Pharma Inc. - Vivaldi Biosciences Inc. - Wittycell S.A.S. - XOMA Ltd. - Zosano Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/zj34n7/influenza About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer
M2 - Wed Jun 05, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g6cvrj/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Pancreatic Cancer products under dev
DiaMedica Announces Initiation of Phase I/II Clinical Trial for Potential First-in-Class Treatment of Type 2 Diabetes
Marketwire Canada - Wed May 01, 7:07AM CDT
DiaMedica Inc. (TSX VENTURE
MA) announces the commencement of its Phase I/II trial with first in human dosing of DM-199; a recombinant protein therapy for the treatment of diabetes and associated complications. As described in the April 8th 2013 press release, the study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of DM-199 in 36 healthy volunteers and in 40 Type 2 diabetic patients. DiaMedica to Present at 15th Annual BIO CEO & Investor Conference
Marketwire - Tue Feb 05, 7:30AM CST
DiaMedica Inc. (TSX VENTURE: DMA), a biotechnology company focused on developing novel treatments for diabetes, announced that Mr. Rick Pauls, Chairman & Chief Executive Officer, will provide a corporate overview at the 15th annual BIO CEO & Investor conference on Monday February 11, 2013 at 10 am ET at the Waldorf Astoria Hotel in New York City.
